Bullish Case: VEEV holds a stage-1 breakout from a deep base at $306 with a 99 IBD Composite Rating, call volume 87% above puts, and bullish risk 28% above bearish. The 11/21 front IV (~31–43%) is far below December's 47–55%, so near-term premium is cheap; Helium's density peaks at $310 vs market's $300, and Veeva Basics' 175+ biotech wins support the growth narrative.

Bearish Case: Helium's AI forecast is -2.51%, December IV (51%) exceeds spot, and the stock is up 26.9% in 90 days at 9.8x book—priced for execution. The Helium PDF's right tail is thin above $360, December puts (300/280P at 50–52 IV) show paid downside protection, and any fiscal Q3 guidance stumble or SPY vol expansion could re-steepen skew into year-end tax-loss season.

Potential Outcomes:

1. 40% Sideways $295–$320 into Dec 19 expiry; falsified by a break of $290 with rising put IV.
2. 25% Grind to $320–$340 on breakout follow-through; falsified if 310C IV doesn't compress below 40.
3. 20% Pullback to $275–$295 on valuation/profit-taking; falsified if 280P IV stays under 50.
4. 10% Drop below $270 if SPY vol expands; falsified by stable SPY downside skew.
5. 5% Rally >$350 on news/guidance; falsified by call IV collapse without price follow-through.

Oracle: defined-risk 12/18 300/280 put spread premium capture fits flat term structure and rich December IV; step aside if downside IV steepens or price closes below $290.

November 10, 2026